Go to Health Care Provider version
| Diagnosis | Medulloblastoma | Study Status | Closed to enrollment |
| Phase | II |
| Age | Child, Adult - (3 years to 39 years) | Randomisation | NO |
| Line of treatment | First line treatment |
| Routes of Treatment Administration | Vismodegib - Oral.
Other drugs are given as usually administered for medulloblastoma therapy |
| Last Posted Update | 2024-03-15 |
| ClinicalTrials.gov # | NCT01878617 |
International Sponsor
St. Jude Children's Research Hospital
Principal Investigators for Canadian Sites
Alberta Children's Hospital - Dr. Lucie Lafay-Cousin
The Hospital for Sick Children - Dr. Ute Bartels
CHU Ste-Justine- Dr. Sébastien Perreault
Centres
Medical contact
Dr. Victor Lewis
Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Study Description
This study will assess the molecular subtype (abbreviated WNT, SHH, Non-WNT, Non-SHH) of patients with medulloblastoma. Based on the subtype And other factors, patients will be assigned to a "risk group", each risk group receiving specific treatment with chemotherapy and radiation therapy.
Patients with a specific molecular subtype called Sonic Hedgehog (SHH) will be treated with a medication taken by mouth, called vismodegib in addition to standard therapy, to directly target the molecular pathway.
Inclusion Criteria
- Patients between 3 and 22 years of age with medulloblastoma.
- Patients between 22 and 40 years with medulloblastoma of the SHH subtype are eligible.
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.
